Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, parallel group study designed to assess the
tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve
cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects
will be randomized to receive one of the conditions for 12 weeks.